{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:34:36Z","timestamp":1790105676336,"version":"4.0.1"},"reference-count":129,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/13543776.2024.2379929","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:05:01Z","timestamp":1722344701000},"page":"807-823","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["SGLT2 inhibitors for the treatment of diabetes: a patent review (2019\u201323)"],"prefix":"10.1080","volume":"34","author":[{"given":"Rahul","family":"Baghel","sequence":"first","affiliation":[{"name":"Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Chhikara","sequence":"additional","affiliation":[{"name":"Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh Kumar","family":"Tamrakar","sequence":"additional","affiliation":[{"name":"Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR) Ghaziabad, Ghaziabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115734"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080008"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.85579"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0666"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-016-0775-x"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18300"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00198"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1301093"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-031620-095920"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05039-w"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020014"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02894.x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.509"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp190"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1029"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00068.2016"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-020-02433-x"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0296-216"},{"key":"e_1_3_5_25_1","first-page":"8S","article-title":"SGLT2 inhibitors for type 2 diabetes mellitus treatment","volume":"32","author":"Plodkowski RA","year":"2015","unstructured":"Plodkowski RA, McGarvey ME, Huribal HM, et al. SGLT2 inhibitors for type 2 diabetes mellitus treatment. Fed Pract. 2015;32:8S.","journal-title":"Fed Pract"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2012.11.002"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050927"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108732"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0256-y"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-106050"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8MD00183A"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8013019"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S212003"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00951-6"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05407-5"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25122757"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0457-8"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12322"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4101-6"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.919907"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00281818"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1997.272.5.G1168"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00118.2002"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0006"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0148-1"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12494"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106415"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071995"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399819666221222160035"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073651"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.01.035"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1008922"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/life12060803"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01430-3"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0005"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-102135"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30621"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071867"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09675-9"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4663-6"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1145587"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3167"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01555-5"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020087"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.10.029"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.680437"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1612879"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2022.100074"},{"key":"e_1_3_5_81_1","unstructured":"Dong H Feng G Wang S et al. Shanghai kely biopharmaceutical Co ltd. Thioglycoside gliflozin analogue preparation method therefor and use thereof. WO2023222144A1. 2023."},{"key":"e_1_3_5_82_1","unstructured":"Xie K Ye F Dai J et al. Inst materia medica cams. Carbon glycoside compound as well as preparation and application thereof. CN112094254A. 2020."},{"key":"e_1_3_5_83_1","unstructured":"Xu G Janssen Pharmaceutica N. Glucopyranose derivatives useful as SGLT2 inhibitors. WO2020084560A1. 2020."},{"key":"e_1_3_5_84_1","unstructured":"Gaul M Kuo G Xu G et al. Janssen Pharmaceutica Nv. Benzocyclobutane derivatives useful as dual SGLT1\/SGLT2 modulators. US10815210B2; 2019 and US2019367469A1. 2020."},{"key":"e_1_3_5_85_1","unstructured":"Chen J Nyamweya N Ong K et al. Lexicon pharmaceuticals Inc. Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2. US2021038626A1. 2021."},{"key":"e_1_3_5_86_1","unstructured":"Eickelmann P Mark M Seman L et al. Boehringer Ingelheim Int. Pharmaceutical composition methods for treating and uses thereof. US2020069713A1. 2020."},{"key":"e_1_3_5_87_1","unstructured":"Chen B. Xuanzhu Beijing medicine tech Co ltd. Deuterium modified C-glycoside derivatives of benzyl-4-chlorophenyl. CN110551088A; 2019 and CN110551088B. 2022."},{"key":"e_1_3_5_88_1","unstructured":"Li X He L Yu J et al. Jiangsu hansoh pharmaceutical group Co ltd. Dapagliflozin crystal form and preparation method and use thereof. US10464915B2; 2019 and US2019218197A1. 2019."},{"key":"e_1_3_5_89_1","unstructured":"Harrison A Kimball D Mabon R et al. Lexicon pharmaceuticals Inc. Sodium glucose Co-transporter inhibitors and methods of their use. US2019099436A1. 2019."},{"key":"e_1_3_5_90_1","unstructured":"Liu J Zhang J Jiang H et al. Pharmaceutical Co ltd. Candesartan compound as well as preparation method and application thereof. CN115894454A. 2023."},{"key":"e_1_3_5_91_1","unstructured":"Huang S Lu X Pan D et al. Shenzhen chipscreen biosciences Co ltd Chengdu chipscreen pharmaceutical Co ltd. Drug combination for treating diabetes mellitus and complications thereof and pharmaceutical composition of drug combination. WO2021218638A1. 2021."},{"key":"e_1_3_5_92_1","unstructured":"Skelly R Hutchinson H Langkilde A et al. AstraZeneca ab. Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes. WO2023144722A1. 2023."},{"key":"e_1_3_5_93_1","unstructured":"Yu G Wang X Hao J et al. Ocean Univ China. Application of galactooligosaccharides and derivatives of galactooligosaccharides as SGLT inhibitor. CN110812364A. 2020."},{"key":"e_1_3_5_94_1","unstructured":"Wang K Wu S Ding B et al. Wanbang Biopharmaceuticals. Pharmaceutical composition of SGLT-2 inhibitor. WO2023173460A1. 2023."},{"key":"e_1_3_5_95_1","unstructured":"Kiresepi E Yildirim E. Santa farma ilac sanayii a S. Multi-layered tablet formulation with extended release layer of metformin hydrochloride. WO2022115053A1. 2022."},{"key":"e_1_3_5_96_1","unstructured":"Bindra D Dali M Parab P et al. AstraZeneca ab. Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate. EP4245299A2 EP4245299A3. 2023."},{"key":"e_1_3_5_97_1","unstructured":"Shah V Redasani V Ghongade A et al. Inventia healthcare ltd. Pharmaceutical composition comprising dapagliflozin. US11660308B2; 2021 and US2021260084A1. 2023."},{"key":"e_1_3_5_98_1","unstructured":"Broedl C Cherney D Daiber A et al. Boehringer Ingelheim Int. Therapeutic uses of empagliflozin. EP4119136A1. 2023."},{"key":"e_1_3_5_99_1","unstructured":"Broedl C Johansen E Kim W et al. Boehringer Ingelheim Int. Pharmaceutical composition methods for treating and uses thereof. US11813275B2; 2023 US2022110961A1. 2022."},{"key":"e_1_3_5_100_1","unstructured":"Tu C Deaton A Zuber J et al. Alnylam pharmaceuticals Inc. Sodium-glucose cotransporter-2 (SGLT2) iRNA compositions and methods of use thereof. WO2022245583A1. 2022."},{"key":"e_1_3_5_101_1","unstructured":"Huh W Lim H Choi J et al. Daewoong pharmaceutical Co ltd. Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae comprising Enavogliflozin. AU2022276995A1. 2022."},{"key":"e_1_3_5_102_1","unstructured":"Reiche DB Kley S. Boehringer Ingelheim Vetmedica Gmbh. Treatment of metabolic disorders in canine animals. EP3485890A1. 2019."},{"key":"e_1_3_5_103_1","unstructured":"Reiche B Haag S Hennings J et al. Boehringer Ingelheim Vetmedica Gmbh. An SGLT-2 inhibitor for use in the treatment of a metabolic disorder in feline animals. EP3862003A1. 2021."},{"key":"e_1_3_5_104_1","unstructured":"Hard M Collinson A Seed B et al. Increvet Inc. Compound for management of feline diabetes. CN113613719A. 2021."},{"key":"e_1_3_5_105_1","unstructured":"Singh B Shingala R Patel M et al. Unison pharmaceuticals pvt ltd. A pharmaceutical composition comprising combination of sitagliptin and empagliflozin. WO2023062648A1. 2023."},{"key":"e_1_3_5_106_1","unstructured":"Singh B Singh P Kathrotia D et al. Unison pharmaceuticals pvt ltd. A pharmaceutical composition comprising combination of dapagliflozin and sitagliptin. WO2023012817A1. 2023."},{"key":"e_1_3_5_107_1","unstructured":"Singh B Singh P Kathrotia D et al. Unison pharmaceuticals pvt ltd. A pharmaceutical composition comprising combination of SGLT2 inhibitor and DPP-IV inhibitor. WO2023007511A1. 2023."},{"key":"e_1_3_5_108_1","unstructured":"Dugi K Mark M Thomas L et al. Boehringer Ingelheim Int. Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative. EP3939577A1. 2022."},{"key":"e_1_3_5_109_1","unstructured":"Macmahon S Rodgers A. The George inst for global health. Low-dose triple combination formulation. WO2020194052A1. 2020."},{"key":"e_1_3_5_110_1","unstructured":"Eickelmann P Mark M Seman Leo J et al. Boehringer Ingelheim Int. Pharmaceutical composition comprising a SGLT2 inhibitor a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof. EP3711751A1. 2020."},{"key":"e_1_3_5_111_1","unstructured":"Mera Y Katsumi S Okuma C et al. Japan tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine. WO2021045159A1. 2021."},{"key":"e_1_3_5_112_1","unstructured":"Chen C Cao G Yang C et al. Jiangsu hengrui medicine Co. Use of SGLT2 inhibitor and DPP-4 inhibitor in preparation of drug for treating diabetes. CN109549939A. 2019."},{"key":"e_1_3_5_113_1","unstructured":"Zhang Y. Liaoning inst science & tech. Western medicine for treating type II diabetes. CN111346232A. 2020."},{"key":"e_1_3_5_114_1","unstructured":"Jung Y Jeon S Kim B et al. Novmetapharma Co ltd. Pharmaceutical composition for preventing or treating diabetes containing zinc salt cyclo-hispro and antidiabetic drug as active ingredients. EP3698801A2. 2020."},{"key":"e_1_3_5_115_1","unstructured":"Davidson M Cui S. New amsterdam pharma B V. Obicetrapib and SGLT2 inhibitor combination. WO2023129595A1. 2023."},{"key":"e_1_3_5_116_1","unstructured":"Yoon M Lee Don G Je in G et al. Ildong pharmaceutical Co ltd. Pharmaceutical composition comprising GPR40 agonist and SGLT-2 inhibitor. WO2022231357A1. 2022."},{"key":"e_1_3_5_117_1","unstructured":"Chen L Ren S Zhang J. Hua medicine ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor. US11813274B2. 2023."},{"key":"e_1_3_5_118_1","unstructured":"Niemoeller E Souhami ESS. Treatment of type 2 diabetes mellitus. CA3150682A1. 2021."},{"key":"e_1_3_5_119_1","unstructured":"Ren X Xu W Zhao G et al. Tianjin institute of pharmaceutical res Co ltd. Medicine composition for treatment of diabetes and preparation method and application thereof. CN109528706A. 2019."},{"key":"e_1_3_5_120_1","unstructured":"Kovatchev B Garcia J Basu A et al. Univ virginia patent foundation. Combination sodium-glucose cotransporter inhibitor (SGLTi)- insulin therapy for glycemic control in type 1 diabetes. WO2023177654A1. 2023."},{"key":"e_1_3_5_121_1","unstructured":"Kim K Kim H Jung H et al. Dong a st Co ltd. Pharmaceutical composition for prevention or treatment of diabetes and metabolic diseases associated therewith. EP4098262A1. 2022."},{"key":"e_1_3_5_122_1","unstructured":"Ji J. Chengdu inst biology cas. Pharmaceutical application of sodium-glucose cotransporter 1 and 2 inhibitors. CN110117304A. 2019."},{"key":"e_1_3_5_123_1","unstructured":"Choung J. Aribio Co ltd. Compositions and methods for preventing and treating neurodegenerative diseases with diabetes. WO2024003787A1. 2024."},{"key":"e_1_3_5_124_1","unstructured":"Choung J. Aribio Co ltd. Composition for prevention and treating dementia with diabetes. KR20220140960A. 2022."},{"key":"e_1_3_5_125_1","unstructured":"Muthaiyyan E Jogani Pranav D Mittal R et al. Zydus Lifesciences ltd. Pharmaceutical compositions comprising a \u03b2-blocker and an SGLT2 inhibitor. WO2023175573A1. 2023."},{"key":"e_1_3_5_126_1","unstructured":"Langkilde. AstraZeneca ab. Methods of treating heart failure with reduced ejection fraction with dapagliflozin. WO2021037400A1. 2021."},{"key":"e_1_3_5_127_1","unstructured":"Langkilde M Astrazeneca A. Methods of treating chronic kidney diseases with dapagliflozin. AU2021202643A1. 2022."},{"key":"e_1_3_5_128_1","unstructured":"Naik RG Ommen ES Rusnak JM et al. Merck sharp & Dohme. SGLT2 inhibitors for treating metabolic disorders in patient with renal impairment or chronic kidney disease. US10500186B2. 2019."},{"key":"e_1_3_5_129_1","unstructured":"Wei R Jin Z Zhang Z et al. Univ Peking third hospital. Use of dapagliflozin and analogue thereof in preparation of drug for preventing and treating male reproductive dysfunction. WO2023109784A1. 2023."},{"key":"e_1_3_5_130_1","unstructured":"Mayoux W. Boehringer Ingelheim Int. Methods and pharmaceutical compositions comprising a SGLT2 inhibitor for treating or improving erectile dysfunction. US2019298749A1. 2019."},{"key":"e_1_3_5_131_1","unstructured":"Xie W Liao L Ding Y et al. Graduate school Shenzhen Tsinghua Univ. Application of diabetes treatment medicine to bacteriostasis. CN112438975A. 2021."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2379929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:57:28Z","timestamp":1727218648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2379929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":129,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/13543776.2024.2379929"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2379929","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}